Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine

被引:6
|
作者
Ceccon, Garry [1 ,2 ]
Wollring, Michael [1 ,2 ]
Brunn, Anna [2 ,3 ]
Deckert, Martina [2 ,3 ]
Waldschmidt, Dirk [2 ,4 ,6 ,7 ,8 ,9 ]
Fink, Gereon R. [1 ,2 ,5 ]
Galldiks, Norbert [1 ,2 ,5 ,6 ,7 ,8 ,9 ]
机构
[1] Univ Cologne, Fac Med, Dept Neurol, Cologne, Germany
[2] Univ Cologne, Univ Hosp Cologne, Cologne, Germany
[3] Univ Cologne, Fac Med, Dept Neuropathol, Cologne, Germany
[4] Univ Cologne, Fac Med, Dept Hepato & Gastroenterol, Cologne, Germany
[5] Forschungszentrum Julich, Inst Neurosci & Med INM 3, Leo Brandt Str 5, DE-52425 Julich, Germany
[6] Univ Aachen, Ctr Integrated Oncol CIO, Aachen, Germany
[7] Univ Bonn, Bonn, Germany
[8] Univ Cologne, Cologne, Germany
[9] Univ Duesseldorf, Dusseldorf, Germany
来源
CASE REPORTS IN ONCOLOGY | 2020年 / 13卷 / 01期
关键词
Blood-brain barrier; Leptomeningeal metastasis; Carcinomatous meningitis; FOLFIRINOX; ALBUMIN-BOUND PACLITAXEL; BREAST-CANCER; PHASE-II; NEOPLASTIC MENINGITIS; NEOADJUVANT TRIAL; BRAIN; CHEMOTHERAPY; TRASTUZUMAB; COMBINATION; TUMOR;
D O I
10.1159/000504697
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Leptomeningeal carcinomatosis is an extremely rare, but devastating complication in pancreatic cancer patients with a poor prognosis despite multimodal treatment. We present a 51-year-old male patient with the very rare condition of leptomeningeal carcinomatosis originating from pancreatic cancer. He presented to our hospital with severe headache and neck stiffness 30 months after systemic chemotherapy. Cerebral and spinal MRI as well as cerebrospinal fluid examination confirmed the diagnosis of leptomeningeal carcinomatosis. The patient responded to gemcitabine plus nab-paclitaxel in terms of elimination of tumor cells from the CSF and concurrent clinical improvement for 3 months. The observed findings suggest that the combination of gemcitabine plus nab-paclitaxel is potentially effective in affected cerebrospinal fluid of pancreatic carcinoma patients.
引用
收藏
页码:35 / 42
页数:8
相关论文
共 50 条
  • [41] A cost-utility analysis of gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer.
    Ko, Yoo-Joung
    Tam, Vincent Channing
    Mittmann, Nicole
    Pasteka, Mark
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] Safety and efficacy of gemcitabine plus nab-paclitaxel therapy in elderly patients with advanced pancreatic cancer
    Aoki, Yu
    Sukawa, Yasutaka
    Kawasaki, Kenta
    Suzuki, Takeshi
    Hirata, Kenro
    Kasuga, Akiyoshi
    Iwasaki, Eisuke
    Hamamoto, Yasuo
    Takaishi, Hiromasa
    Kanai, Takanori
    ANNALS OF ONCOLOGY, 2017, 28
  • [43] Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer
    Nakano, Shintaro
    Komatsu, Yoshito
    Kawamoto, Yasuyuki
    Saito, Rika
    Ito, Ken
    Nakatsumi, Hiroshi
    Yuki, Satoshi
    Sakamoto, Naoya
    MEDICINE, 2020, 99 (39) : E22250
  • [44] Nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Resected Pancreatic Cancer in a Phase III Trial (APACT)
    Tempero, Margaret
    Cardin, Dana
    Biankin, Andrew V.
    Goldstein, David
    Moore, Malcolm
    O'Reilly, Eileen
    Philip, Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Li, Mingyu
    Lu, Brian
    GASTROENTEROLOGY, 2015, 148 (04) : S944 - S944
  • [45] Gemcitabine plus nab-paclitaxel with initial dose reduction for older patients with advanced pancreatic cancer
    Ibusuki, Mayu
    Inoue, Tadahisa
    Kitano, Rena
    Sakamoto, Kazumasa
    Kimoto, Satoshi
    Kobayashi, Yuji
    Ohashi, Tomohiko
    Sumida, Yoshio
    Nakade, Yukiomi
    Ito, Kiyoaki
    Yoneda, Masashi
    JOURNAL OF GERIATRIC ONCOLOGY, 2021, 12 (01) : 118 - 121
  • [46] The Role of nab-Paclitaxel Plus Gemcitabine Therapy for Recurrent Pancreatic Cancer Refractory to Gemcitabine and S-1
    Kagawa, S.
    Yoshitomi, H.
    Shimizu, H.
    Ohtsuka, M.
    Kato, A.
    Furukawa, K.
    Takayashiki, T.
    Takano, S.
    Kuboki, S.
    Suzuki, D.
    Sakai, N.
    Miyazaki, M.
    PANCREAS, 2015, 44 (08) : 1385 - 1385
  • [47] ECONOMIC EVALUATION OF NAB-PACLITAXEL PLUS GEMCITABINE VERSUS GEMCITABINE ALONE FOR THE MANAGEMENT OF METASTATIC PANCREATIC CANCER IN GREECE
    Fragoulakis, V
    Papakostas, P.
    Pentheroudakis, G.
    Dervenis, C.
    Maniadakis, N.
    VALUE IN HEALTH, 2014, 17 (07) : A632 - A632
  • [48] A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis
    Naminatsu Takahara
    Yousuke Nakai
    Hironori Ishigami
    Kei Saito
    Tatsuya Sato
    Ryunosuke Hakuta
    Kazunaga Ishigaki
    Tomotaka Saito
    Tsuyoshi Hamada
    Suguru Mizuno
    Hirofumi Kogure
    Hiroharu Yamashita
    Hiroyuki Isayama
    Yasuyuki Seto
    Kazuhiko Koike
    Investigational New Drugs, 2021, 39 : 175 - 181
  • [49] Multicenter retrospective study of gemcitabine plus nab-paclitaxel for elderly patients with advanced pancreatic cancer
    Ozaka, M.
    Kobayashi, S.
    Ikeda, M.
    Ueno, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 270 - 270
  • [50] Gemcitabine (G) plus nab-paclitaxel (nab-P) plus chemoradiation (CRT) in locally advanced pancreatic cancer (LAPC)
    Olowokure, Olugbenga Olanrele
    Bedoya, Ivan Dario
    Mierzwa, Michelle Lynn
    Torregroza, Maria Patricia
    Dwivedi, Alok Kumar
    Wang, Jiang
    Smith, Milton T.
    Schmulewitz, Nathan
    Kucera, Stephen
    Choe, Kyuran Ann
    Ristagno, Ross
    Rudich, Steven
    Sussman, Jeffrey J.
    Ahmad, Syed A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)